Implementación de un sistema informático para mejorar la gestión de la salud ocupacional en la empresa Expreso Extra, Lima, 2022

El objetivo del estudio fue implementar un sistema informático para mejorar la gestión de salud ocupacional en la empresa Expreso Extra en Lima, este sistema se desarrolló en base a los lineamientos de Scrum. De enfoque cuantitativo, tipo aplicada y nivel explicativo. Con una muestra de 84 colaboradores del área de producción de Expreso Extra. Se utilizó el cuestionario y la ficha de observación para la recolección de datos. Con respecto a la gestión de la salud ocupacional se obtuvo que en su planeación incrementó de 6.67% a 66.67%; la organización mejoró en un 52%; la ejecución se optimizó de 11.90% a 71.43% y, la evaluación pasó de 7.43% a 60%. En conclusión, la implementación del sistema informático bajo plataforma web permitió registrar fichas de atención médica, gestión de incidentes, calendarización de actividades y reducción de tiempos de búsqueda de información, mejorando significativamente la gestión de la salud ocupacional en la empresa Expreso Extra en Lima.Campus Lima Nort

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo